Drug intelligence / Profile preview

LA-859

Development stage: Preclinical
Lead developer: Allero Therapeutics
Modality: Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Buccal, Oral

Overview

**LA-859** is an Allero Therapeutics preclinical candidate for food and pollen allergies developed using the company’s SOMIT specific oromucosal immunotherapy platform. It is described as a mouth-patch-based antigen-specific immunotherapy intended to present relevant allergens to the oral mucosa together with tolerogenic bacterial particles containing Toll-like receptor-binding proteins, with the aim of inducing durable immune tolerance and allergen desensitization rather than broadly suppressing immunity. Allero describes SOMIT as combining a tolerance-inducing agent with targeted antigen delivery to the oral mucosa. ([allerotherapeutics.com](https://www.allerotherapeutics.com/technology-1))

Beyond the preview

Go deeper on LA-859.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LA-859.

Explore the full profile